bioAffinity Technologies, Inc. (BIAF)
NASDAQ: BIAF · Real-Time Price · USD
0.2550
-0.0069 (-2.63%)
Mar 31, 2025, 1:09 PM EDT - Market open
Company Description
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung.
It offers CyPath lung, a diagnostic test, for early detection of lung cancer. The company was incorporated in 2014 and is based in San Antonio, Texas.
bioAffinity Technologies, Inc.
| Country | United States |
| Founded | 2014 |
| IPO Date | Sep 1, 2022 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 75 |
| CEO | Maria Zannes |
Contact Details
Address: 22211 West Interstate 10, Suite 1206 San Antonio, Texas 78257 United States | |
| Phone | 210 698 5334 |
| Website | bioaffinitytech.com |
Stock Details
| Ticker Symbol | BIAF |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $6.13 |
| CIK Code | 0001712762 |
| CUSIP Number | 09076W109 |
| ISIN Number | US09076W1099 |
| Employer ID | 46-5211056 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Maria Zannes J.D. | Founder, President, Chief Executive Officer and Director |
| Steven Girgenti | Founder and Executive Chairman of the Board |
| J. Michael Edwards CPA, M.B.A. | Chief Financial Officer and Principal Accounting Officer |
| Xavier T. Reveles M.S. | Chief Operating Officer |
| Dr. William Bauta Ph.D. | Chief Science Officer |
| Timothy P. Zannes J.D. | Executive Vice President, Secretary and General Counsel |
| Julie Anne Overton | Director of Communications |
| Dallas J. Coleman | Vice President of sales |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 31, 2025 | 8-K | Current Report |
| Mar 7, 2025 | 8-K | Current Report |
| Feb 27, 2025 | 8-K | Current Report |
| Feb 25, 2025 | 424B5 | Filing |
| Feb 25, 2025 | 424B5 | Filing |
| Feb 7, 2025 | 8-K | Current Report |
| Jan 14, 2025 | 8-K | Current Report |
| Dec 23, 2024 | 8-K | Current Report |
| Dec 20, 2024 | 8-K | Current Report |
| Dec 9, 2024 | 424B3 | Prospectus |